(0.26%) 5 536.00 points
(0.27%) 39 576 points
(0.27%) 19 981 points
(0.61%) $82.04
(-1.88%) $2.55
(0.35%) $2 347.70
(0.14%) $29.60
(-0.61%) $995.80
(-0.26%) $0.931
(-0.35%) $10.64
(-0.19%) $0.789
(2.07%) $87.50
Live Chart Being Loaded With Signals
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States...
Stats | |
---|---|
今日成交量 | 17 873 |
平均成交量 | 38 033 |
市值 | 31.62M |
EPS | $-0.190 ( Q1 | 2024-05-13 ) |
下一个收益日期 | ( $-0.360 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.670 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0120 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-10 | Kahn Scott D | Buy | 15 000 | Stock Option(right to buy) |
2024-06-10 | Kahn Scott D | Buy | 0 | |
2024-06-10 | Stokes Frank | Buy | 9 000 | Stock Option(right to buy) |
2024-06-10 | Hooker Ana | Buy | 9 000 | Stock Option(right to buy) |
2024-06-10 | Kim Paul | Buy | 9 000 | Stock Option(right to buy) |
INSIDER POWER |
---|
83.55 |
Last 94 transactions |
Buy: 1 716 109 | Sell: 483 792 |
Exagen Inc 财务报表
Annual | 2023 |
营收: | $52.55M |
毛利润: | $29.46M (56.06 %) |
EPS: | $-1.340 |
FY | 2023 |
营收: | $52.55M |
毛利润: | $29.46M (56.06 %) |
EPS: | $-1.340 |
FY | 2022 |
营收: | $45.56M |
毛利润: | $21.35M (46.86 %) |
EPS: | $-2.77 |
FY | 2021 |
营收: | $48.30M |
毛利润: | $27.71M (57.37 %) |
EPS: | $-1.680 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
XGN | Q1 | 2024 | Exagen, Inc. First Quarter 2024 Financial Report |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Exagen Inc
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。